



(51) International Patent Classification:

C07D 471/10 (2006.01) A61K 31/506 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/054432

(22) International Filing Date:

04 November 2024 (04.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/547,350 04 November 2023 (04.11.2023) US
63/674,598 23 July 2024 (23.07.2024) US

(71) Applicant: SYNDAX PHARMACEUTICALS, INC.

[US/US]; 35 Gatehouse Drive, Building D, Floor 3,
Waltham, Massachusetts 02451 (US).

(72) Inventors: MAROLEWSKI, Ariane; c/o Syndax Phar-

maceuticals, Inc., 35 Gatehouse Drive, Building D, Floor
3, Waltham, Massachusetts 02451 (US). KATTUBOINA,
Venkata A.; c/o Syndax Pharmaceuticals, Inc., 35 Gate-
house Drive, Building D, Floor 3, Waltham, Massachu-

setts 02451 (US). FULZELE, Suniket; c/o Syndax Phar-
maceuticals, Inc., 35 Gatehouse Drive, Building D, Floor 3,
Waltham, Massachusetts 02451 (US).

(74) Agent: ERLACHER, Heidi A. et al.; Cooley LLP, ATTN:

IP Docketing Department, 1299 Pennsylvania Avenue, NW,
Suite 700, Washington, District of Columbia 20004-2400
(US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: SALTS AND POLYMORPHIC FORMS OF REVUMENIB





FIG. 1B



(A)

(57) Abstract: The present disclosure relates to a novel salt and salt forms of Compound (A). The disclosure is also directed to pharmaceutical compositions containing Compound (A) citrate salt or salt forms and to the therapeutic use of such salts, salt forms, and compositions thereof.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

30 May 2025 (30.05.2025)